34 results on '"Vedel-Krogh, Signe"'
Search Results
2. Risk of ulcerative colitis and Crohn’s disease in smokers lacks causal evidence
- Author
-
Pedersen, Kasper Mønsted, Çolak, Yunus, Vedel-Krogh, Signe, Kobylecki, Camilla Jannie, Bojesen, Stig Egil, and Nordestgaard, Børge Grønne
- Published
- 2022
- Full Text
- View/download PDF
3. Laboratory assessment of antiphospholipid syndrome: Laboratory data.
- Author
-
Kobylecki, Camilla J., Vedel‐Krogh, Signe, Afzal, Shoaib, and Goetze, Jens P.
- Subjects
- *
ANTICOAGULANTS , *STATISTICAL correlation , *MEDICAL information storage & retrieval systems , *REPEATED measures design , *INTERPROFESSIONAL relations , *BLOOD coagulation disorders , *RESEARCH funding , *AUTOANTIBODIES , *DESCRIPTIVE statistics , *CLINICAL pathology , *RESEARCH , *PHYSICIAN practice patterns , *MEDICAL screening , *MEDICAL laboratories , *CONFIDENCE intervals , *QUALITY assurance , *ANTIPHOSPHOLIPID syndrome , *THROMBOSIS - Abstract
Introduction: Thorough assessment of the antiphospholipid syndrome (APS) includes retesting of positive antiphospholipid antibody (aPL) tests after at least 12 weeks, and a full antiphospholipid antibody profile. To what extent this work‐up is done in clinical practice is unknown. Methods: Data on 25 116 in‐ and out‐hospital patients tested for the presence of lupus anticoagulant (LA), the aPL which most strongly correlates with thrombosis, was extracted from the laboratory information system of the only laboratory that performs LA tests in the Capital Region, Denmark. We estimated fraction of repeated tests, tests repeated within the recommended time span, and fraction with a full aPL profile. Results: Out of 25 116 patients, 843 were positive for LA (3.3%), and 3948 results were inconclusive (16%). Only 51% (95% CI of the proportion: 48%–54%) (n = 431) of positive tests were repeated. The proportion of inconclusive LA test results increased from 13% (12%–15%) in 2009 to 20% (19%–22%) in 2020. Out of the positive tests repeated within the first year, only 60/353 (17%; 13%–21%) were repeated within 12–16 weeks; 177/353 (50%; 45%–55%) were re‐tested within the first 12 weeks of first positive test result. The proportion of patients with a full antiphospholipid antibody profile increased from 161/1978 (8%) in 2010 to 1041/1978 (43%) in 2020. Conclusion: We found several issues with the laboratory workup of APS. This indicates a need for increased awareness of comprehensive laboratory assessment of possible APS as well as a closer collaboration between the laboratory and clinicians. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Asthma and COPD versus phenotypic traits: Toward precision medicine in chronic airway disease
- Author
-
Vedel-Krogh, Signe, Nielsen, Sune Fallgaard, Nordestgaard, Børge Grønne, Lange, Peter, and Vestbo, Jørgen
- Published
- 2021
- Full Text
- View/download PDF
5. Low density lipoprotein cholesterol and apolipoprotein b do not capture the cardiovascular disease risk from lipoprotein(a)
- Author
-
Thomas, Peter, Vedel-Krogh, Signe, Kamstrup, Pia, and Nordestgaard, Børge
- Published
- 2024
- Full Text
- View/download PDF
6. Impaired renal function with elevated remnant cholesterol related to risk of atherosclerotic cardiovascular disease: The copenhagen general population study
- Author
-
Elías-López, Daniel, Vedel-Krogh, Signe, Kobylecki, Camilla Jannie, Wadström, Benjamin, and Nordestgaard, Børge
- Published
- 2024
- Full Text
- View/download PDF
7. The Christmas holidays are immediately followed by a period of hypercholesterolemia
- Author
-
Vedel-Krogh, Signe, Kobylecki, Camilla J., Nordestgaard, Børge G., and Langsted, Anne
- Published
- 2019
- Full Text
- View/download PDF
8. Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when?
- Author
-
Thomas, Peter E., Vedel-Krogh, Signe, and Nordestgaard, Børge G.
- Published
- 2024
- Full Text
- View/download PDF
9. Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events.
- Author
-
Thomas, Peter E., Vedel-Krogh, Signe, Nielsen, Sune F., Nordestgaard, Børge G., and Kamstrup, Pia R.
- Subjects
- *
ABDOMINAL aortic aneurysms , *PERIPHERAL vascular diseases , *CLINICAL trials , *AORTIC rupture - Abstract
Lp(a) (lipoprotein[a])-lowering therapy to reduce cardiovascular disease is under investigation in phase 3 clinical trials. High Lp(a) may be implicated in peripheral artery disease (PAD), abdominal aortic aneurysms (AAAs), and major adverse limb events (MALE). The authors investigated the association of high Lp(a) levels and corresponding LPA genotypes with risk of PAD, AAA, and MALE. The authors included 108,146 individuals from the Copenhagen General Population Study. During follow-up, 2,450 developed PAD, and 1,251 AAAs. Risk of MALE was assessed in individuals with PAD at baseline and replicated in the Copenhagen City Heart Study. Higher Lp(a) was associated with a stepwise increase in risk of PAD and AAA (P for trend <0.001). For individuals with Lp(a) levels ≥99th (≥143 mg/dL, ≥307 nmol/L) vs <50th percentile (≤9 mg/dL, ≤17 nmol/L), multivariable-adjusted HRs were 2.99 (95% CI: 2.09-4.30) for PAD and 2.22 (95% CI: 1.21-4.07) for AAA. For individuals with PAD, the corresponding incidence rate ratio for MALE was 3.04 (95% CI: 1.55-5.98). Per 50 mg/dL (105 nmol/L) genetically higher Lp(a) risk ratios were 1.39 (95% CI: 1.24-1.56) for PAD and 1.21 (95% CI: 1.01-1.44) for AAA, consistent with observational risk ratios of 1.33 (95% CI: 1.24-1.43) and 1.27 (95% CI: 1.15-1.41), respectively. In women smokers aged 70 to 79 years with Lp(a) <50th and ≥99th percentile, absolute 10-year risks of PAD were 8% and 21%, and equivalent risks in men 11% and 29%, respectively. For AAA, corresponding risks were 2% and 4% in women, and 5% and 12% in men. High Lp(a) levels increased risk of PAD, AAA, and MALE by 2- to 3-fold in the general population, opening opportunities for prevention given future Lp(a)-lowering therapies. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. From plasma triglycerides to triglyceride metabolism: effects on mortality in the Copenhagen General Population Study.
- Author
-
Johansen, Mia Ø, Afzal, Shoaib, Vedel-Krogh, Signe, Nielsen, Sune F, Smith, George Davey, and Nordestgaard, Børge G
- Subjects
TRIGLYCERIDES ,BODY mass index ,CANCER-related mortality ,METABOLISM ,MORTALITY - Abstract
Aims It is unclear whether higher triglyceride metabolism per se contributes to mortality separate from elevated triglyceride-rich lipoproteins and body mass index. This study tested the hypotheses that higher triglyceride metabolism, measured as higher plasma glycerol and β-hydroxybutyrate, is associated with increased all-cause, cardiovascular, cancer, and other mortality. Methods and results This study included 30 000 individuals nested within 109 751 individuals from the Copenhagen General Population Study. During a median follow-up of 10.7 years, 9897 individuals died (2204 from cardiovascular, 3366 from cancer, and 2745 from other causes), while none were lost to follow-up. In individuals with glycerol >80 µ mol/L (highest fourth) vs. individuals with glycerol <52 µ mol/L (lowest fourth), the multivariable adjusted hazard ratio for all-cause mortality was 1.31 (95% confidence interval 1.22–1.40). In individuals with β-hydroxybutyrate >154 µ mol/L (highest fourth) vs. individuals with β-hydroxybutyrate <91 µ mol/L (lowest fourth), the multivariable adjusted hazard ratio for all-cause mortality was 1.18 (1.11–1.26). Corresponding values for higher plasma glycerol and β-hydroxybutyrate were 1.37 (1.18–1.59) and 1.18 (1.03–1.35) for cardiovascular mortality, 1.24 (1.11–1.39) and 1.16 (1.05–1.29) for cancer mortality, and 1.45 (1.28–1.66) and 1.23 (1.09–1.39) for other mortality, respectively. Results were robust to exclusion of first years of follow-up, to stratification for covariates including plasma triglycerides and body mass index, and to further adjustments. Conclusion This study observed an increased risk of all-cause, cardiovascular, cancer, and other mortality with higher triglyceride metabolism. This was not explained by higher plasma triglycerides and body mass index. The hypothesis studied in the present paper should be further validated by isotope flux studies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Plasma Vitamin D Is Not Associated with Moderate-to-Severe Psoriasis: Results from Danish General Population Studies
- Author
-
Näslund-Koch, Charlotte, Vedel-Krogh, Signe, Bojesen, Stig E., and Skov, Lone
- Published
- 2023
- Full Text
- View/download PDF
12. Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein.
- Author
-
Thomas, Peter E, Vedel-Krogh, Signe, Kamstrup, Pia R, and Nordestgaard, Børge G
- Subjects
AORTIC stenosis ,C-reactive protein ,MYOCARDIAL infarction ,CARDIOVASCULAR diseases - Abstract
Aims Recent evidence suggest that the lipoprotein(a)-associated risk of atherosclerotic cardiovascular disease (ASCVD) may be observed only in individuals with low-grade systemic inflammation. It was hypothesized that high lipoprotein(a) is a main driver for the risk of ASCVD, myocardial infarction, and aortic valve stenosis irrespective of C-reactive protein levels. Methods and results A total of 68 090 individuals from the Copenhagen General Population Study, a prospective cohort study, were included. During a median follow-up of 8.1 years, 5104 individuals developed ASCVD, 2432 myocardial infarction, and 1220 aortic valve stenosis. The risk of ASCVD, myocardial infarction, and aortic valve stenosis increased with higher values of both lipoprotein(a) and C-reactive protein. For individuals with lipoprotein(a) in the 91st–100th percentiles (≥70 mg/dl, ≥147 nmol/l) vs. the 1st–33rd percentiles (≤6 mg/dl, ≤9 nmol/l), the multivariable-adjusted hazard ratio for ASCVD was 1.61 (95% confidence interval 1.43–1.81) for those with C-reactive protein <2 mg/l and 1.57 (1.36–1.82) for those with C-reactive protein ≥2 mg/l (P for interaction = 0.87). The corresponding values were 2.08 (1.76–2.45) and 1.65 (1.34–2.04) for myocardial infarction, and 2.01 (1.59–2.55) and 1.73 (1.31–2.27) for aortic valve stenosis, respectively (P for interaction = 0.15 and = 0.18). The highest absolute 10-year risks were found in men aged 70–79 years with lipoprotein(a) levels in the 91st–100th percentiles and C-reactive protein ≥2 mg/l, with 34% for ASCVD, 19% for myocardial infarction, and 13% for aortic valve stenosis. The corresponding values in women were 20%, 10%, and 8%, respectively. Conclusion High lipoprotein(a) was a main driver for the risk of ASCVD, myocardial infarction, and aortic valve stenosis independent of C-reactive protein levels. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study
- Author
-
Vedel-Krogh, Signe, Nielsen, Sune F., Lange, Peter, Vestbo, Jørgen, and Nordestgaard, Børge G.
- Published
- 2016
- Full Text
- View/download PDF
14. Non-alcoholic fatty liver disease is not a causal risk factor for psoriasis: A Mendelian randomization study of 108,835 individuals.
- Author
-
Näslund-Koch, Charlotte, Bojesen, Stig Egil, Gluud, Lise Lotte, Skov, Lone, and Vedel-Krogh, Signe
- Subjects
NON-alcoholic fatty liver disease ,FATTY liver ,PSORIASIS - Abstract
Background: Psoriasis is observationally associated with a higher risk of nonalcoholic fatty liver disease (NAFLD); however, the causal relationship between the two diseases remains unclear. Objective: We hypothesized that individuals with NAFLD or elevated liver fat content have higher risk of psoriasis and that NAFLD is a causal risk factor for psoriasis. We tested this using a Mendelian randomization approach. Methods: We included 108,835 individuals from the Danish general population, including 1,277 individuals with psoriasis and 802 individuals with NAFLD according to ICD codes. To estimate liver fat content, a subset of the participants (N = 7,416) also had a CT scan performed. First, we tested whether a diagnosis of NAFLD or elevated liver fat content was observationally associated with risk of psoriasis. Subsequently, we used the genetic variants PNPLA3 and TM6SF2, both strongly associated with NAFLD and high liver fat content, to test whether NAFLD was causally associated with increased risk of psoriasis. Results: Observationally, individuals with vs. without a diagnosis of NAFLD had higher risk of psoriasis with an odds ratio of 2.03 (95% confidence interval 1.28- 3.21). The risk of psoriasis increased in a stepwise manner with increasing liver fat content with an odds ratio of 5.00 (2.63-9.46) in individuals in the highest quartile of liver fat content compared to individuals in the lowest quartile. In genetic analyses, PNPLA3 and TM6SF2 were both associated with increased risk of NAFLD but not with increased risk of psoriasis. Conclusion: Observationally, a diagnosis of NAFLD or elevated liver fat content was associated with higher risk of psoriasis. However, using genetic variants as a proxy for NAFLD, we did not find evidence of a causal relationship between NAFLD and psoriasis. Thus, the observational association between NAFLD and psoriasis is presumably a result of shared confounding factors or reverse causation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Traditional and Non-traditional Cardiovascular Risk Factors and Cardiovascular Disease in Women with Psoriasis.
- Author
-
NÄSLUND-KOCH, Charlotte, VEDEL-KROGH, Signe, BOJESEN, Stig Egil, and SKOV, Lone
- Subjects
- *
CARDIOVASCULAR diseases , *CARDIOVASCULAR diseases risk factors , *HEART failure , *PSORIASIS , *CEREBROVASCULAR disease - Abstract
Women with cardiovascular disease are underdiagnosed, undertreated and under-represented in research. Even though the increased risk of cardiovascular disease among patients with psoriasis is well established, only a few studies have examined women with psoriasis. This study examined the prevalence of cardiovascular risk factors and cardiovascular disease among women with psoriasis. Using the Copenhagen City Heart Study and the Copenhagen General Population Study, 66,420 women were included in a cross-sectional design. Of these, 374 (0.56%) women had hospital-diagnosed psoriasis. Women with vs without hospital-diagnosed psoriasis had higher odds ratios of having traditional cardiovascular risk factors, including hypertriglyceridaemia, smoking, obesity, type 2 diabetes, and low physical activity, and of having nontraditional cardiovascular risk factors, including low level of education, high level of psychosocial stress, and lowgrade inflammation. Compared with women from the general population, the multivariable adjusted odds ratio of heart failure and ischaemic cerebrovascular disease in women with hospital-diagnosed psoriasis was 2.51 (95% confidence interval 1.33-4.73) and 2.06 (1.27-3.35). In conclusion, women with hospital-diagnosed psoriasis have a higher prevalence of traditional and nontraditional cardiovascular risk factors, and increased risk of heart failure and ischaemic cerebrovascular disease, even after adjusting for these cardiovascular risk factors. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Reply to: “Seasonal variations of lipid profiles in a French cohort”
- Author
-
Langsted, Anne, Vedel-Krogh, Signe, Kobylecki, Camilla J., and Nordestgaard, Børge G.
- Published
- 2019
- Full Text
- View/download PDF
17. Per-Particle Triglyceride-Rich Lipoproteins Imply Higher Myocardial Infarction Risk Than Low-Density Lipoproteins: Copenhagen General Population Study.
- Author
-
Johansen, Mia Ø., Vedel-Krogh, Signe, Nielsen, Sune F., Afzal, Shoaib, Davey Smith, George, and Nordestgaard, Børge G.
- Published
- 2021
- Full Text
- View/download PDF
18. Very Low-Density Lipoprotein Cholesterol May Mediate a Substantial Component of the Effect of Obesity on Myocardial Infarction Risk: The Copenhagen General Population Study.
- Author
-
Johansen, Mia Ø., Nielsen, Sune F., Afzal, Shoaib, Vedel-Krogh, Signe, Smith, George Davey, and Nordestgaard, Børge G.
- Published
- 2021
- Full Text
- View/download PDF
19. Smoking Reduces Plasma Bilirubin: Observational and Genetic Analyses in the Copenhagen General Population Study.
- Author
-
Kodal, Jakob B, Çolak, Yunus, Kobylecki, Camilla J, Vedel-Krogh, Signe, Nordestgaard, Børge G, and Afzal, Shoaib
- Subjects
BILIRUBIN ,SMOKING statistics ,SMOKING cessation ,SMOKING ,DISEASE risk factors ,PLASMA currents ,TOBACCO & cancer ,RESEARCH ,CHOLINERGIC receptors ,RESEARCH methodology ,GENETIC polymorphisms ,ALLELES ,EVALUATION research ,MEDICAL cooperation ,COMPARATIVE studies ,GENOTYPES ,LONGITUDINAL method - Abstract
Introduction: Observational studies have found lower concentrations of plasma bilirubin in current smokers compared with former and never smokers. However, whether there is a causal relationship between smoking and bilirubin is unknown. In a Mendelian randomization analysis, we tested the hypothesis that higher tobacco consumption is causally associated with lower concentrations of plasma bilirubin.Methods: We genotyped 103 557 individuals aged 20-100 years from the Copenhagen General Population Study for the CHRNA3 rs1051730 genotype, known to be associated with higher tobacco consumption. Tobacco consumption was defined as daily and cumulative tobacco consumption.Results: In observational multivariable-adjusted analyses, a 10 g/day higher daily tobacco consumption was associated with a 0.28 µmol/L (95% confidence interval = 0.20 to 0.35) lower concentration of plasma bilirubin in current smokers, and a 10 pack-year higher cumulative tobacco consumption was associated with a 0.19 µmol/L (0.17 to 0.21) lower concentration of plasma bilirubin in former and current smokers. Using the CHRNA3 rs1051730 genotype as a proxy for daily and cumulative tobacco consumption, the difference in plasma bilirubin per T-allele was -0.12 µmol/L (-0.23 to -0.002) in current smokers and -0.09 µmol/L (-0.15 to -0.01) in current and former smokers combined. Furthermore, observationally bilirubin concentrations increased with time from smoking cessation in former smokers.Conclusion: Higher daily and cumulative tobacco consumption were associated with lower concentrations of plasma bilirubin in observational and genetic analyses, suggesting that the association is causal.Implications: Our results are compatible with two possible interpretations of previous observational studies, either that bilirubin is a mediator of smoking-induced respiratory disease or that the association between plasma bilirubin and respiratory disease stems from residual confounding because of smoking. Future studies should examine whether bilirubin is a causal risk factor for respiratory disease, or merely a marker of smoking status. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
20. Plasma urate, lung function and chronic obstructive pulmonary disease: a Mendelian randomisation study in 114 979 individuals from the general population.
- Author
-
Kobylecki, Camilla J., Vedel-Krogh, Signe, Afzal, Shoaib, Nielsen, Sune F., and Nordestgaard, Børge G.
- Subjects
COMPARATIVE studies ,GENETICS ,OBSTRUCTIVE lung diseases ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,PULMONARY function tests ,URIC acid ,EVALUATION research ,PREDICTIVE tests ,GENOTYPES - Abstract
Background: Urate is a strong antioxidant in plasma and may protect against lung function impairment. We tested the hypothesis that high plasma urate is causally associated with better lung function and low risk of respiratory symptoms and COPD.Methods: We measured lung function and plasma urate in 114 979 individuals from the Copenhagen City Heart Study and the Copenhagen General Population Study and genotyped for SLC2A9 rs7442295 and ABCG2 rs2231142 variants, previously associated with high plasma urate, in 110 152 individuals.Results: In the two studies combined, multivariable-adjusted 100 µmol/L higher plasma urate was associated with -1.54% (95% CI -1.67 to -1.40) lower FEV1 % predicted and -1.57% (95% CI -1.69 to -1.44) lower FVC % predicted observationally; the corresponding estimates for genetically determined 100 µmol/L higher plasma urate were -0.46% (95% CI -1.17 to 0.25) and -0.40% (95% CI -1.03 to 0.23). High plasma urate was also associated with higher risk of respiratory symptoms; however, genetically determined high plasma urate was not associated with respiratory symptoms. Finally, we identified 14 151 individuals with COPD and found ORs of 1.08 (95% CI 1.06 to 1.11) for COPD observationally and 1.01 (95% CI 0.88 to 1.15) genetically per 100 µmol/L higher plasma urate.Conclusion: High plasma urate was associated with worse lung function and higher risk of respiratory symptoms and COPD in observational analyses; however, genetically high plasma urate was not associated with any of these outcomes. Thus, our data do not support a direct causal relationship. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
21. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.
- Author
-
Burgess, Stephen, Ference, Brian A., Staley, James R., Freitag, Daniel F., Mason, Amy M., Nielsen, Sune F., Willeit, Peter, Young, Robin, Surendran, Praveen, Karthikeyan, Savita, Bolton, Thomas R., Peters, James E., Kamstrup, Pia R., Tybjærg-Hansen, Anne, Benn, Marianne, Langsted, Anne, Schnohr, Peter, Vedel-Krogh, Signe, Kobylecki, Camilla J., and Ford, Ian
- Published
- 2018
- Full Text
- View/download PDF
22. Genetic variants affecting cross-sectional lung function in adults show little or no effect on longitudinal lung function decline.
- Author
-
John, Catherine, Artigas, María Soler, Hui, Jennie, Nielsen, Sune Fallgaard, Rafaels, Nicholas, Paré, Peter D., Hansel, Nadia N., Shrine, Nick, Kilty, Iain, Malarstig, Anders, Jelinsky, Scott A., Vedel-Krogh, Signe, Barnes, Kathleen, Hall, Ian P., Beilby, John, Musk, Arthur W., Nordestgaard, Børge G., James, Alan, Wain, Louise V., and Tobin, Martin D.
- Subjects
HUMAN genetic variation ,PULMONARY function tests ,OBSTRUCTIVE lung diseases ,PHENOTYPES ,FOLLOW-up studies (Medicine) ,DISEASE susceptibility ,GENETICS ,LONGITUDINAL method ,RESEARCH funding ,RESPIRATION ,RISK assessment ,SPIROMETRY ,TIME ,CROSS-sectional method ,DISEASE progression ,SEQUENCE analysis ,GENOTYPES - Abstract
Background: Genome-wide association studies have identified numerous genetic regions that influence cross-sectional lung function. Longitudinal decline in lung function also includes a heritable component but the genetic determinants have yet to be defined.Objectives: We aimed to determine whether regions associated with cross-sectional lung function were also associated with longitudinal decline and to seek novel variants which influence decline.Methods: We analysed genome-wide data from 4167 individuals from the Busselton Health Study cohort, who had undergone spirometry (12 695 observations across eight time points). A mixed model was fitted and weighted risk scores were calculated for the joint effect of 26 known regions on baseline and longitudinal changes in FEV1 and FEV1/FVC. Potential additional regions of interest were identified and followed up in two independent cohorts.Results: The 26 regions previously associated with cross-sectional lung function jointly showed a strong effect on baseline lung function (p=4.44×10-16 for FEV1/FVC) but no effect on longitudinal decline (p=0.160 for FEV1/FVC). This was replicated in an independent cohort. 39 additional regions of interest (48 variants) were identified; these associations were not replicated in two further cohorts.Conclusions: Previously identified genetic variants jointly have a strong effect on cross-sectional lung function in adults but little or no effect on the rate of decline of lung function. It is possible that they influence COPD risk through lung development. Although no genetic variants have yet been associated with lung function decline at stringent genome-wide significance, longitudinal change in lung function is heritable suggesting that there is scope for future discoveries. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
23. Association of Blood Eosinophil and Blood Neutrophil Counts with Asthma Exacerbations in the Copenhagen General Population Study.
- Author
-
Vedel-Krogh, Signe, Fallgaard Nielsen, Sune, Lange, Peter, Vestbo, Jørgen, and Grønne Nordestgaard, Børge
- Published
- 2017
- Full Text
- View/download PDF
24. Reply to: "Seasonal variations of lipid profiles in a French cohort".
- Author
-
Vedel-Krogh, Signe, Kobylecki, Camilla J., Nordestgaard, Børge G., and Langsted, Anne
- Subjects
- *
LIPIDS , *LIPOPROTEINS , *SEASONAL variations of diseases , *EUROPEAN integration - Published
- 2019
- Full Text
- View/download PDF
25. Morbidity and Mortality in 7,684 Women According to Personal Hair Dye Use: The Copenhagen City Heart Study followed for 37 Years.
- Author
-
Vedel-Krogh, Signe, Nielsen, Sune F., Schnohr, Peter, and Nordestgaard, Børge G.
- Subjects
- *
HAIR dyeing & bleaching , *SKIN diseases , *DISEASES in women , *AROMATIC amines , *CARCINOGENS , *ALLERGIES - Abstract
Background: Permanent hair dye contains aromatic amines which are carcinogenic, and can cause allergic skin reactions. In the long term personal use of hair dye might therefore influence both morbidity and mortality. Objectives: We tested the hypothesis that personal use of hair dye in women is associated with increased morbidity and mortality in the general population. Methods: We included 7,684 women from the Copenhagen City Heart Study with information on the use of personal hair dye. We assessed the risk of cancer, skin diseases, other morbidities, and mortality during a median follow-up of 27 years (range 0–37). Results: The multivariable adjusted hazard ratio for malignant melanoma in women with versus without personal use of hair dye was 2.07 (95% confidence interval 1.25–3.42). There was no increased risk of other cancer types. For other skin diseases and other major causes of morbidity we found no differences between the two groups, except for a minor excess of digestive diseases and increased risk of Parkinson’s disease among women using hair dye. Finally, we found no difference in all-cause mortality comparing women using personal hair dye or not. After correction for multiple comparisons, none of the results remained significant. However, in sensitivity analysis the excess risk of malignant melanoma remained increased with a hazard ratio of 2.58 (95%CI 1.33–5.03) among users of personal hair dye. Conclusions: Personal use of hair dye does not have major influences on morbidity and mortality. Our finding of a 2-fold risk of malignant melanoma in women using hair dye is hypothesis generating. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. Statin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease.
- Author
-
Vedel-Krogh, Signe, Nielsen, Sune F., and Nordestgaard, Børge G.
- Subjects
- *
STATINS (Cardiovascular agents) , *MORTALITY , *FOLLOW-up studies (Medicine) , *INTERSTITIAL lung diseases , *DIAGNOSIS , *PATIENTS - Abstract
Introduction: We hypothesized that statin use begun before the diagnosis of interstitial lung disease is associated with reduced mortality. Methods: We studied all patients diagnosed with interstitial lung disease in the entire Danish population from 1995 through 2009, comparing statin use versus no statin use in a nested 1:2 matched study. Results: The cumulative survival as a function of follow-up time from the date of diagnosis of interstitial lung disease (n = 1,786+3,572) and idiopathic lung fibrosis (n = 261+522) was higher for statin users versus never users (log-rank: P = 7·10−9 and P = 0.05). The median survival time in patients with interstitial lung disease was 3.3 years in statin users and 2.1 years in never users. Corresponding values in patients with idiopathic lung fibrosis were 3.4 versus 2.4 years. After multivariable adjustment, the hazard ratio for all-cause mortality for statin users versus never users was 0.73 (95% confidence interval, 0.68 to 0.79) in patients with interstitial lung disease and 0.76 (0.62 to 0.93) in patients with idiopathic lung fibrosis. Results were robust in all sensitivity analyses. Conclusion: Among patients with interstitial lung disease statin use was associated with reduced all-cause mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
27. Adherence to general national dietary guidelines and risk of psoriasis: results from a general population study of 105,332 individuals.
- Author
-
Näslund-Koch C, Kjeldsen EW, Vedel-Krogh S, Bojesen SE, and Skov L
- Abstract
Background: It is unknown if an unhealthy diet can affect the risk of developing psoriasis., Objectives: We hypothesised that individuals with an unhealthy diet have increased risk of prevalent and incident psoriasis., Methods: We included 105,332 adults from the Copenhagen General Population Study, who were invited between 2003 and 2015. Response-rate was 43%. An unhealthy versus healthy diet was defined according to adherence to general national dietary guidelines. The participants were grouped into low, intermediate, and high adherence to general national dietary guidelines based on information from a food frequency questionnaire. Identification of psoriasis was made using ICD codes., Results: Of the 105,332 individuals, 580 had a diagnosis of psoriasis at the time of enrolment and 640 received a diagnosis during the median follow-up of 9 years. Risk of prevalent psoriasis increased according to non-adherence to general national dietary guidelines in a stepwise manner with an age and sex adjusted odds ratio of 1.70 (95% confidence interval 1.26-2.30) in individuals with low vs. high adherence to dietary guidelines. Results were similar in a multivariable adjusted model. Prospective analyses adjusted for age and sex showed a weak association between non-adherence to dietary guidelines and risk of incident psoriasis (P for trend 0.04). This association disappeared, when adjusting for multiple confounders (P for trend 0.50)., Conclusions: Although individuals with psoriasis have an unhealthier diet, diet alone does not appear to independently increase the risk of developing psoriasis., (© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
28. Smoking is an independent but not a causal risk factor for moderate to severe psoriasis: A Mendelian randomization study of 105,912 individuals.
- Author
-
Näslund-Koch C, Vedel-Krogh S, Bojesen SE, and Skov L
- Subjects
- Humans, Risk Factors, Tobacco Smoking, Causality, Mendelian Randomization Analysis methods, Smoking
- Abstract
Background: Smoking is strongly associated with higher risk of psoriasis in several observational studies; however, whether this association is causal or can be explained by confounding or reverse causation is not fully understood. Randomized controlled trials are the gold standard when examining causality; however, when this method is not feasible, the Mendelian randomization design is an alternative. Herein genetic variants can be used as robust proxies for modifiable exposures and thereby avoiding confounding and reverse causation.In this study, we hypothesized that smoking is an independent and causal risk factor for psoriasis and tested this using a Mendelian randomization design., Methods: We used data from the Copenhagen General Population Study including 105,912 individuals with full information on lifestyle factors, biochemistry, and genotype data. In total, 1,240 cases of moderate to severe psoriasis were included to investigate the association between smoking and psoriasis. To assess causality of the association, we used the genetic variant CHRNA3 rs1051730, where the T-allele is strongly associated with high lifelong cumulative smoking, as a proxy for smoking., Results: In observational analyses, the multivariable adjusted hazard ratio of developing moderate to severe psoriasis was 1.64 (95% confidence interval: 1.35-2.00) in ever smokers with ≤ 20 pack-years and 2.23 (1.82-2.73) in ever smokers with > 20 pack-years compared to never smokers. In genetic analyses, the odds ratio of developing moderate to severe psoriasis was 1.05 (0.95-1.16) per CHRNA3 rs10511730 T-allele in ever smokers., Conclusion: Smoking was an independent risk factor for moderate to severe psoriasis in observational analyses. However, using a genetic variant as a robust proxy for smoking, we did not find this association to be causal., Competing Interests: CN-K has served as an investigator for Galderma, Abbvie, LEO Pharma, and CSL Behring. LS has served as an investigator for AbbVie, Pfizer, Sanofi, Janssen Cilag, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Regeneron, Galderma and LEO Pharma. LS has received research funding from Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the LEO Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker for AbbVie, Eli Lilly, Novartis, Pfizer, and LEO Pharma, Janssen Cilag, UCB, Almirall, Bristol-Myers Squibb, and Sanofi. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Näslund-Koch, Vedel-Krogh, Bojesen and Skov.)
- Published
- 2023
- Full Text
- View/download PDF
29. Complement C3 and allergic asthma: a cohort study of the general population.
- Author
-
Vedel-Krogh S, Rasmussen KL, Nordestgaard BG, and Nielsen SF
- Subjects
- Cohort Studies, Eosinophils, Humans, Leukocyte Count, Asthma epidemiology, Asthma genetics, Complement C3 analysis, Complement C3 genetics
- Abstract
Complement C3 plays a role in asthma development and severity. We tested the hypothesis that high plasma complement C3 concentration is associated with high risks of asthma hospitalisation and exacerbation.We prospectively assessed the risk of asthma hospitalisation in 101 029 individuals from the Copenhagen General Population Study with baseline measurements of plasma complement C3, and genotyped for rs1065489, rs429608 and rs448260 determining levels of complement C3. Risk of asthma exacerbation was further assessed in 2248 individuals with allergic asthma.The multivariable adjusted hazard ratio of asthma hospitalisation was 1.23 (95% CI 1.04-1.45) for individuals in the highest tertile (>1.19 g·L
-1 ) of plasma complement C3 compared with those in the lowest tertile (<1.03 g·L-1 ). The C3 rs448260 genotype was associated with risk of asthma hospitalisation with an observed hazard ratio of 1.17 (95% CI 1.06-1.28) for the CC genotype compared with the AA genotype. High plasma complement C3 was associated with high levels of blood eosinophils and IgE (p for trends ≤6×10-9 ), but only the SKIV2L rs429608 genotype was positively associated with blood eosinophil count (p=3×10-4 ) and IgE level (p=3×10-4 ). In allergic asthma, the multivariable adjusted incidence rate ratio for risk of exacerbation was 1.69 (95% CI 1.06-2.72) for individuals in the highest plasma complement C3 tertile (>1.24 g·L-1 ) versus the lowest (<1.06 g·L-1 ).In conclusion, a high concentration of plasma complement C3 was associated with a high risk of asthma hospitalisation in the general population and with a high risk of asthma exacerbation in individuals with allergic asthma. Our findings support a causal role of the complement system in asthma severity., Competing Interests: Conflict of interest: S. Vedel-Krogh has nothing to disclose. Conflict of interest: K.L. Rasmussen has nothing to disclose. Conflict of interest: B.G. Nordestgaard has nothing to disclose. Conflict of interest: S.F. Nielsen has nothing to disclose., (Copyright ©ERS 2021.)- Published
- 2021
- Full Text
- View/download PDF
30. The search for the "healthy" blood eosinophil count.
- Author
-
Vedel-Krogh S
- Subjects
- Health Status, Humans, Leukocyte Count, Eosinophils, Pulmonary Disease, Chronic Obstructive
- Abstract
Competing Interests: Conflict of interest: S. Vedel-Krogh has nothing to disclose.
- Published
- 2020
- Full Text
- View/download PDF
31. Vitamin D and Inflammatory Bowel Disease: Mendelian Randomization Analyses in the Copenhagen Studies and UK Biobank.
- Author
-
Lund-Nielsen J, Vedel-Krogh S, Kobylecki CJ, Brynskov J, Afzal S, and Nordestgaard BG
- Subjects
- Aged, Biological Specimen Banks, Cholestanetriol 26-Monooxygenase genetics, Colitis, Ulcerative blood, Colitis, Ulcerative epidemiology, Colitis, Ulcerative genetics, Crohn Disease blood, Crohn Disease epidemiology, Crohn Disease genetics, Cross-Sectional Studies, Cytochrome P450 Family 2 genetics, Denmark epidemiology, Female, Genotype, Humans, Inflammatory Bowel Diseases epidemiology, Inflammatory Bowel Diseases genetics, Male, Mendelian Randomization Analysis, Middle Aged, Prospective Studies, United Kingdom epidemiology, Vitamin D blood, Vitamin D Deficiency epidemiology, Vitamin D Deficiency genetics, Inflammatory Bowel Diseases blood, Vitamin D analogs & derivatives, Vitamin D Deficiency blood
- Abstract
Context: Vitamin D may be a modifiable risk factor for inflammatory bowel disease (IBD)., Objectives: We tested the hypothesis that plasma 25-hydroxyvitamin D levels are causally associated with risk of Crohn disease (CD) and ulcerative colitis (UC)., Design, Setting, Patients, and Interventions: We used a Mendelian randomization design to study 120,013 individuals from the Copenhagen City Heart Study, the Copenhagen General Population Study, and a Copenhagen-based cohort of patients with IBD. Of these, 35,558 individuals had plasma 25-hydroxyvitamin D measurements available, and 115,110 were genotyped for rs7944926 and rs11234027 in DHCR7 and rs10741657 and rs12794714 in CYP2R1, all variants associated with plasma 25-hydroxyvitamin D levels. We identified 653 cases of CD and 1265 cases of UC, of which 58 and 113, respectively, had 25-hydroxyvitamin D measurements available. We also included genetic data from 408,455 individuals from the UK Biobank, including 1707 CD cases and 3147 UC cases., Main Outcome Measure: Hazard ratios for higher plasma 25-hydroxyvitamin D levels., Results: The multivariable-adjusted hazard ratios for 10 nmol/L higher 25-hydroxyvitamin D level were 1.04 (95% CI: 0.93 to 1.16) for CD and 1.13 (95% CI: 1.06 to 1.21) for UC. A combined 25-hydroxyvitamin D allele score was associated with a 1.4-nmol/L increase in plasma 25-hydroxyvitamin D level and hazard ratios of 0.98 (95% CI: 0.94 to 1.03) for CD and 1.01 (95% CI: 0.97 to 1.05) for UC. Combining genetic data from the Copenhagen studies and the UK Biobank, genetically determined vitamin D did not appear to influence the risk of CD or UC., Conclusions: Our results do not support a major role for vitamin D deficiency in the development of IBD.
- Published
- 2018
- Full Text
- View/download PDF
32. Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD.
- Author
-
Vedel-Krogh S, Nordestgaard BG, Lange P, Vestbo J, and Nielsen SF
- Subjects
- Adrenal Cortex Hormones therapeutic use, Aged, Denmark epidemiology, Disease Progression, Female, Forced Expiratory Volume, Humans, Leukocyte Count, Male, Middle Aged, Multivariate Analysis, Pneumonia epidemiology, Prospective Studies, Pulmonary Disease, Chronic Obstructive drug therapy, Regression Analysis, Smoking adverse effects, Eosinophils cytology, Hospitalization statistics & numerical data, Pneumonia etiology, Pulmonary Disease, Chronic Obstructive blood, Pulmonary Disease, Chronic Obstructive complications
- Abstract
Blood eosinophil count in chronic obstructive pulmonary disease (COPD) is associated with higher exacerbation rate and favourable response to corticosteroids; however, frequent exacerbations and use of inhaled corticosteroids could elevate pneumonia risk. We tested the hypothesis that high blood eosinophil counts are associated with high risk of pneumonia in individuals with severe COPD from the general population.We included 7180 individuals with COPD from the Copenhagen General Population Study, including 643 with forced expiratory volume in 1 s (FEV
1 ) <50% predicted between 2003 and 2011. All primary discharge diagnoses of pneumonia during follow-up were recorded.Among individuals with COPD and FEV1 <50% pred, the multivariable adjusted incidence rate ratio was 2.17 (95% CI 1.31-3.58) for pneumonia comparing individuals with blood eosinophil counts ≥0.34×109 cells·L-1 versus <0.34×109 cells·L-1 In individuals with clinical COPD, defined by recent exacerbation, ≥10 pack-years of smoking and FEV1 <70% pred, the corresponding risk was 4.52 (2.11-9.72). Risk of pneumonia did not differ by blood eosinophil count in individuals with COPD and FEV1 ≥50% pred.In individuals with COPD and FEV1 <50% pred, blood eosinophil count ≥0.34×109 cells·L-1 was associated with high risk of hospitalisation due to pneumonia., Competing Interests: Conflict of interest: J. Vestbo has received personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, GlaxoSmithKline and Novartis, outside the submitted work. Conflict of interest: P. Lange has received grants and personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Novartis and GlaxoSmithKline, and personal fees from Norpharma, Takeda and Pfizer, outside the submitted work., (Copyright ©ERS 2018.)- Published
- 2018
- Full Text
- View/download PDF
33. AHRR hypomethylation, lung function, lung function decline and respiratory symptoms.
- Author
-
Kodal JB, Kobylecki CJ, Vedel-Krogh S, Nordestgaard BG, and Bojesen SE
- Subjects
- Aged, Cross-Sectional Studies, Denmark, Epigenesis, Genetic, Female, Follow-Up Studies, Genome, Human, Humans, Male, Middle Aged, Multivariate Analysis, Prospective Studies, Registries, Respiratory Function Tests, Smoking, Spirometry, Basic Helix-Loop-Helix Transcription Factors genetics, DNA Methylation, Lung physiology, Repressor Proteins genetics, Respiration
- Abstract
Epigenome-wide association studies have shown a consistent association between smoking exposure and hypomethylation in the aryl hydrocarbon receptor repressor ( AHRR ) gene (cg05575921). We tested the hypothesis that AHRR hypomethylation is associated with low lung function, steeper lung function decline, and respiratory symptoms in the general population. AHRR methylation extent was measured in 9113 individuals from the 1991-1994 examination of the Copenhagen City Heart Study, using bisulfite-treated leukocyte DNA. Spirometry at the time of blood sampling was available for all individuals. Lung function was measured again for 4532 of these individuals in 2001-2003.Cross-sectionally, a 10% lower methylation extent was associated with a 0.2 z-score (95% CI 0.1-0.2) lower forced expiratory volume in 1 s (FEV
1 ) after multivariable adjustment including smoking. Hypomethylation was also associated with a lower z-score for both forced vital capacity (FVC) and FEV1 /FVC. In prospective analyses, individuals in the lowest versus highest tertile of methylation extent had a steeper decline in FEV1 /height3 (p for examination×methylation interaction=0.003) and FVC/height3 (p=0.01), but not FEV1 /FVC (p=0.08). Multivariable-adjusted odds ratios per 10% lower methylation extent were 1.31 (95% CI 1.18-1.45) for chronic bronchitis and 1.21 (95% CI 1.13-1.30) for any respiratory symptoms. AHRR hypomethylation was associated with low lung function, steeper lung function decline, and respiratory symptoms., Competing Interests: Conflict of interest: None declared., (Copyright ©ERS 2018.)- Published
- 2018
- Full Text
- View/download PDF
34. TP53 Arg72Pro, mortality after cancer, and all-cause mortality in 105,200 individuals.
- Author
-
Kodal JB, Vedel-Krogh S, Kobylecki CJ, Nordestgaard BG, and Bojesen SE
- Subjects
- Adult, Aged, Aged, 80 and over, Alleles, Cardiovascular Diseases epidemiology, Cardiovascular Diseases genetics, Cardiovascular Diseases mortality, Denmark epidemiology, Female, Genotyping Techniques, Humans, Male, Melanoma epidemiology, Middle Aged, Risk Assessment, Survival Analysis, Young Adult, Melanoma genetics, Melanoma mortality, Mutant Proteins genetics, Mutation, Missense, Tumor Suppressor Protein p53 genetics
- Abstract
Rs1042522 (Arg72Pro) is a functional polymorphism of TP53. Pro72 has been associated with lower all-cause mortality and lower mortality after cancer. We hypothesized that TP53 Pro72 is associated with lower mortality after cancer, lower all-cause mortality, and with increased cancer incidence in the general population in a contemporary cohort. We genotyped 105,200 individuals aged 20-100 years from the Copenhagen General Population Study, recruited in 2003-2013, and followed them in Danish health registries. During follow-up 5,531 individuals died and 5,849 developed cancer. Hazard ratios for mortality after cancer were 1.03 (95% confidence interval:0.93-1.15) for Arg/Pro and 0.96 (95% CI:0.79-1.18) for Pro/Pro versus Arg/Arg. Hazard ratios for all-cause mortality were 0.99 (95% CI:0.93-1.04) for Arg/Pro and 1.09 (95% CI:0.98-1.21) for Pro/Pro versus Arg/Arg. Risk of cancer specific mortality, cardiovascular mortality, and respiratory mortality were not associated with Arg72Pro genotype overall; however, in exploratory subgroup analyses, genotype-associated risks of malignant melanoma and diabetes were altered. Considering multiple comparisons the latter findings may represent play of chance. The TP53 Arg72Pro genotype was not associated with mortality after cancer, all-cause mortality, or cancer incidence in the general population in a contemporary cohort. Our main conclusion is therefore a lack of reproducing an effect of TP53 Arg72Pro genotype on mortality.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.